D&D Pharmatech Inc.
A GLP-1 peptide-based drug developer with an oral obesity treatment partnered with Pfizer and pipelines for MASH, Parkinson's, and Alzheimer's disease.
As of 2026-10-09, D&D Pharmatech Inc. has 12 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2014 and listed on KOSDAQ in 2024, D&D Pharmatech develops innovative therapies for metabolic and neurodegenerative diseases based on GLP-1 and other peptide technologies. Its core pipeline includes an oral obesity treatment partnered with Pfizer, MASH (metabolic dysfunction-associated steatohepatitis) treatment DD01, Parkinson's and Alzheimer's disease treatment NLY01, and fibrotic disease treatment TLY012, leveraging drug delivery technologies such as PEGylation and its ORALINK platform for converting injectables to oral formulations. Through its U.S. subsidiary Neuraly Inc. it develops PET imaging biomarkers, Valted Seq, Inc. is building the single-cell genomic analysis platform SCADE, and it holds a 15% stake in Z-Alpha Therapeutics, classified as an affiliate, which is developing next-generation alpha radiation cancer therapies.
R&D and key agreements
Source: DART corporate disclosure경구용 비만치료제 · 비만 · GLP-1-based, partnered with Pfizer (formerly Metsera, acquired by Pfizer Nov 2025)
DD01 · MASH(대사이상 관련 지방간염)
NLY01 · 파킨슨병, 알츠하이머병
TLY012 · 섬유화질환
PET 이미징 바이오마커 개발 · Conducted by subsidiary Neuraly Inc.
SCADE · 퇴행성 뇌질환 · AI-based single-cell genomic analysis platform built by Valted Seq, Inc.
Key disclosures
KRX KIND via OpenDART- Management[기재정정]투자판단관련주요경영사항(임상시험결과) (대사이상지방간염 (MASH) 치료제 DD01의 미국 임상 제2상 Topline data 수령)2026-05-27
Publications
PubMed · affiliation-matched- Peptide mapping analysis of synthetic semaglutide and liraglutide for generic development of drugs originating from recombinant DNA technology.
Journal of pharmaceutical and biomedical analysis · 2025-04 · Kim SH, Kim SS, Kim HJ 외 2
- TRAIL receptor agonist TLY012 in combination with PD-1 inhibition promotes tumor regression in an immune-competent mouse model of pancreatic ductal adenocarcinoma.
American journal of cancer research · 2025-01 · Louie AD, Huntington KE, Lee Y 외 5
- TRAIL agonists rescue mice from radiation-induced lung, skin, or esophageal injury.
The Journal of clinical investigation · 2025-01 · Strandberg J, Louie A, Lee S 외 21
- Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2023-04 · Lee TS, Park EJ, Choi M 외 6
- ONC201/TIC10 plus TLY012 anti-cancer effects via apoptosis inhibitor downregulation, stimulation of integrated stress response and death receptor DR5 in gastric adenocarcinoma.
American journal of cancer research · 2023-01 · Parker CS, Zhou L, Prabhu VV 외 4
- Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals.
Pharmaceuticals (Basel, Switzerland) · 2022-12 · Kim JC, Park EJ, Na DH
- Cleavage-Responsive Biofactory T Cells Suppress Infectious Diseases-Associated Hypercytokinemia.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022-09 · Kim H, Son B, Seo EU 외 10
- Nano Differential Scanning Fluorimetry-Based Thermal Stability Screening and Optimal Buffer Selection for Immunoglobulin G.
Pharmaceuticals (Basel, Switzerland) · 2021-12 · Kim SH, Yoo HJ, Park EJ 외 1
- Recent Progress in Drug Release Testing Methods of Biopolymeric Particulate System.
Pharmaceutics · 2021-08 · Kim Y, Park EJ, Kim TW 외 1
- Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer's disease.
Acta neuropathologica communications · 2021-04 · Park JS, Kam TI, Lee S 외 17
Show 2 more publications
- Dual peptide-dendrimer conjugate inhibits acetylation of transforming growth factor β-induced protein and improves survival in sepsis.
Biomaterials · 2020-07 · Lee W, Park EJ, Kwon OK 외 7
- Emerging PEGylated non-biologic drugs.
Expert opinion on emerging drugs · 2019-06 · Park EJ, Choi J, Lee KC 외 1
Patents
KIPRIS · applicant-matchedPublished · 2026-09 · Application 1020260165957
Published · 2026-09 · Application 1020260165956
PCT · Published · 2025-11 · Application PCT/US2025/055735
US · Published · 2025-04 · Application 19194851
TW · Published · 2023-05 · Application 112119719
TW · Published · 2023-05 · Application 112119720
Published · 2023-05 · Application 1020247043291
US · Published · 2023-05 · Application 18869210
US · Published · 2023-05 · Application 18869214
EP · Published · 2023-05 · Application 23811290.8
Show 34 more patents
EP · Published · 2023-05 · Application 23811291.6
PCT · Published · 2023-05 · Application PCT/IB2023/055433
PCT · Published · 2023-05 · Application PCT/IB2023/055432
Rejected · 2022-09 · Application 1020220113764
US · Published · 2022-09 · Application 18690140
EP · Published · 2022-09 · Application 22867718.3
PCT · Published · 2022-09 · Application PCT/KR2022/013497
Registered · 2021-11 · Application 1020210167781
Registered · 2021-11 · Application 1020210167782
US · Published · 2021-11 · Application 18039184
EP · Published · 2021-11 · Application 21898733.7
EP · Published · 2021-11 · Application 21897261.0
PCT · Published · 2021-11 · Application PCT/KR2021/017802
PCT · Published · 2021-11 · Application PCT/IB2021/022237
Registered · 2021-08 · Application 1020210110117
US · Published · 2020-11 · Application 17778759
EP · Published · 2020-11 · Application 20891706.2
PCT · Published · 2020-11 · Application PCT/KR2020/016531
CN · Published · 2020-05 · Application 202080039061.2
Registered · 2020-05 · Application 1020200065484
US · Published · 2020-05 · Application 17615504
EP · Published · 2020-05 · Application 20814628.2
PCT · Published · 2020-05 · Application PCT/KR2020/007053
Registered · 2019-11 · Application 1020190153983
CN · Published · 2019-07 · Application 201980047328.X
US · Registered · 2019-07 · Application 17261144
EP · Published · 2019-07 · Application 19838006.5
PCT · Published · 2019-07 · Application PCT/KR2019/008918
Rejected · 2019-05 · Application 1020190060513
Registered · 2019-05 · Application 1020190053879
Registered · 2018-07 · Application 1020180083946
US · Registered · 2017-01 · Application 15413029
EP · Registered · 2015-04 · Application 15721078.2
US · Registered · 2015-03 · Application 14645276
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive9
- OpenAIOAI-SearchBot101
- PerplexityPerplexityBot4
- AnthropicClaudeBot2
- MicrosoftBingbot1
- GoogleGoogleOther1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for D&D Pharmatech Inc. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition